| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Toxoplasma | 65 | 2024 | 114 | 10.590 |
Why?
|
| Toxoplasmosis | 34 | 2024 | 68 | 7.340 |
Why?
|
| Toxoplasmosis, Congenital | 26 | 2024 | 47 | 4.670 |
Why?
|
| Toxoplasmosis, Animal | 14 | 2019 | 19 | 2.350 |
Why?
|
| Antiprotozoal Agents | 15 | 2013 | 30 | 2.160 |
Why?
|
| Antibodies, Protozoan | 16 | 2024 | 47 | 2.110 |
Why?
|
| Protozoan Proteins | 12 | 2018 | 76 | 1.640 |
Why?
|
| Enoyl-(Acyl-Carrier-Protein) Reductase (NADH) | 11 | 2013 | 12 | 1.630 |
Why?
|
| Protozoan Vaccines | 5 | 2016 | 11 | 1.630 |
Why?
|
| Toxoplasmosis, Ocular | 10 | 2018 | 17 | 1.410 |
Why?
|
| Triclosan | 9 | 2013 | 10 | 1.240 |
Why?
|
| Immunoglobulin M | 9 | 2024 | 153 | 1.180 |
Why?
|
| Epitopes, T-Lymphocyte | 5 | 2016 | 99 | 1.160 |
Why?
|
| Coccidiostats | 4 | 2013 | 4 | 1.150 |
Why?
|
| Pregnancy Complications, Parasitic | 8 | 2024 | 17 | 1.000 |
Why?
|
| Plasmodium falciparum | 11 | 2020 | 57 | 0.990 |
Why?
|
| Antigens, Protozoan | 8 | 2020 | 22 | 0.810 |
Why?
|
| CD8-Positive T-Lymphocytes | 7 | 2020 | 696 | 0.740 |
Why?
|
| Spiramycin | 2 | 2021 | 2 | 0.730 |
Why?
|
| Pregnancy | 19 | 2024 | 3244 | 0.720 |
Why?
|
| Neglected Diseases | 1 | 2021 | 2 | 0.710 |
Why?
|
| Immunoglobulin G | 10 | 2024 | 480 | 0.690 |
Why?
|
| Observational Studies as Topic | 1 | 2021 | 63 | 0.690 |
Why?
|
| Animals | 52 | 2020 | 28902 | 0.680 |
Why?
|
| Pregnancy Complications, Infectious | 1 | 2021 | 98 | 0.650 |
Why?
|
| Mice | 30 | 2020 | 12697 | 0.650 |
Why?
|
| Parasites | 1 | 2020 | 12 | 0.640 |
Why?
|
| Interferon-gamma | 6 | 2014 | 479 | 0.580 |
Why?
|
| Hydrocephalus | 2 | 2015 | 80 | 0.570 |
Why?
|
| Genotype | 7 | 2018 | 1888 | 0.550 |
Why?
|
| Mice, Transgenic | 10 | 2020 | 1604 | 0.550 |
Why?
|
| Female | 49 | 2024 | 51570 | 0.550 |
Why?
|
| Oocysts | 4 | 2017 | 8 | 0.530 |
Why?
|
| HLA-A Antigens | 3 | 2016 | 39 | 0.530 |
Why?
|
| Cytokines | 4 | 2018 | 889 | 0.520 |
Why?
|
| Cat Diseases | 1 | 2017 | 19 | 0.510 |
Why?
|
| Pets | 1 | 2017 | 10 | 0.510 |
Why?
|
| Dog Diseases | 1 | 2017 | 36 | 0.500 |
Why?
|
| HLA-B7 Antigen | 3 | 2020 | 7 | 0.500 |
Why?
|
| Adjuvants, Immunologic | 4 | 2020 | 176 | 0.480 |
Why?
|
| Triazines | 2 | 2008 | 55 | 0.480 |
Why?
|
| Quinolones | 1 | 2016 | 57 | 0.470 |
Why?
|
| Toxoplasmosis, Cerebral | 3 | 2009 | 4 | 0.470 |
Why?
|
| Antiparasitic Agents | 3 | 2013 | 9 | 0.470 |
Why?
|
| Oxidoreductases | 4 | 2004 | 112 | 0.460 |
Why?
|
| Encephalitis | 2 | 2008 | 46 | 0.460 |
Why?
|
| Antimalarials | 5 | 2012 | 22 | 0.450 |
Why?
|
| Humans | 70 | 2024 | 98135 | 0.450 |
Why?
|
| Fathers | 1 | 2015 | 46 | 0.450 |
Why?
|
| Infant, Newborn | 11 | 2024 | 2531 | 0.440 |
Why?
|
| Family Health | 1 | 2015 | 156 | 0.440 |
Why?
|
| Drug Discovery | 1 | 2016 | 120 | 0.440 |
Why?
|
| Models, Molecular | 10 | 2018 | 1391 | 0.440 |
Why?
|
| Cells, Cultured | 10 | 2020 | 2855 | 0.430 |
Why?
|
| Nervous System Diseases | 1 | 2016 | 169 | 0.430 |
Why?
|
| Sulfadiazine | 7 | 2008 | 23 | 0.430 |
Why?
|
| Drug Design | 4 | 2013 | 135 | 0.420 |
Why?
|
| Cluster Analysis | 1 | 2015 | 402 | 0.420 |
Why?
|
| Benzamides | 2 | 2012 | 260 | 0.410 |
Why?
|
| Autoimmune Diseases | 1 | 2016 | 259 | 0.410 |
Why?
|
| Spiro Compounds | 1 | 2013 | 24 | 0.410 |
Why?
|
| Mice, Inbred C57BL | 11 | 2016 | 3598 | 0.390 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 4 | 2017 | 373 | 0.390 |
Why?
|
| Genes, MHC Class I | 4 | 2010 | 46 | 0.380 |
Why?
|
| Nanoparticles | 2 | 2020 | 218 | 0.380 |
Why?
|
| Salicylanilides | 1 | 2012 | 1 | 0.380 |
Why?
|
| Proctocolectomy, Restorative | 2 | 2006 | 117 | 0.380 |
Why?
|
| Morpholinos | 1 | 2012 | 13 | 0.370 |
Why?
|
| Promoter Regions, Genetic | 2 | 2018 | 977 | 0.370 |
Why?
|
| Fibroblasts | 7 | 2013 | 767 | 0.360 |
Why?
|
| Chorioretinitis | 3 | 2008 | 5 | 0.360 |
Why?
|
| Infant | 12 | 2021 | 3332 | 0.360 |
Why?
|
| Mice, Inbred BALB C | 7 | 2014 | 1110 | 0.350 |
Why?
|
| Genetic Predisposition to Disease | 4 | 2018 | 2555 | 0.350 |
Why?
|
| Adaptor Proteins, Vesicular Transport | 1 | 2012 | 53 | 0.350 |
Why?
|
| Parasitology | 1 | 2011 | 2 | 0.350 |
Why?
|
| Indoles | 1 | 2013 | 334 | 0.350 |
Why?
|
| Peptides | 2 | 2014 | 669 | 0.350 |
Why?
|
| Vaccines, Subunit | 3 | 2020 | 54 | 0.350 |
Why?
|
| Point-of-Care Testing | 3 | 2022 | 29 | 0.350 |
Why?
|
| H-2 Antigens | 3 | 2010 | 58 | 0.340 |
Why?
|
| Polymorphism, Single Nucleotide | 5 | 2018 | 2558 | 0.340 |
Why?
|
| Phenyl Ethers | 1 | 2010 | 13 | 0.330 |
Why?
|
| Ribosomal Proteins | 1 | 2010 | 47 | 0.320 |
Why?
|
| Carrier Proteins | 2 | 2013 | 667 | 0.310 |
Why?
|
| Enzyme Inhibitors | 7 | 2013 | 642 | 0.310 |
Why?
|
| Structure-Activity Relationship | 6 | 2013 | 425 | 0.310 |
Why?
|
| Disease Models, Animal | 7 | 2016 | 2572 | 0.310 |
Why?
|
| Pyridines | 2 | 2010 | 318 | 0.310 |
Why?
|
| Genetic Therapy | 1 | 2012 | 373 | 0.310 |
Why?
|
| Nitriles | 1 | 2010 | 171 | 0.310 |
Why?
|
| Amino Acid Sequence | 8 | 2011 | 2005 | 0.300 |
Why?
|
| Prevalence | 5 | 2021 | 1383 | 0.290 |
Why?
|
| Cats | 4 | 2017 | 282 | 0.290 |
Why?
|
| Prenatal Diagnosis | 3 | 2024 | 107 | 0.290 |
Why?
|
| Cell Cycle | 1 | 2010 | 518 | 0.290 |
Why?
|
| Cell Proliferation | 3 | 2013 | 1790 | 0.280 |
Why?
|
| Nerve Degeneration | 1 | 2008 | 78 | 0.280 |
Why?
|
| Apicomplexa | 2 | 2012 | 5 | 0.270 |
Why?
|
| Child, Preschool | 10 | 2016 | 4006 | 0.270 |
Why?
|
| Sensitivity and Specificity | 5 | 2024 | 1948 | 0.270 |
Why?
|
| Infectious Disease Transmission, Vertical | 5 | 2010 | 34 | 0.270 |
Why?
|
| Molecular Sequence Data | 9 | 2011 | 2896 | 0.260 |
Why?
|
| Cryptosporidium parvum | 2 | 2005 | 5 | 0.260 |
Why?
|
| Child | 13 | 2016 | 7699 | 0.260 |
Why?
|
| Agglutination Tests | 2 | 2017 | 11 | 0.250 |
Why?
|
| HIV Infections | 1 | 2016 | 1018 | 0.240 |
Why?
|
| Shikimic Acid | 2 | 2006 | 2 | 0.240 |
Why?
|
| Genes, MHC Class II | 3 | 2002 | 28 | 0.240 |
Why?
|
| Mass Screening | 1 | 2011 | 745 | 0.230 |
Why?
|
| Drug Hypersensitivity | 1 | 2006 | 38 | 0.230 |
Why?
|
| Molecular Structure | 5 | 2013 | 305 | 0.230 |
Why?
|
| Adolescent | 11 | 2024 | 10097 | 0.230 |
Why?
|
| Brain | 6 | 2011 | 2448 | 0.230 |
Why?
|
| Colombia | 3 | 2024 | 20 | 0.230 |
Why?
|
| Serologic Tests | 2 | 2018 | 42 | 0.220 |
Why?
|
| Pyrimethamine | 7 | 2008 | 19 | 0.220 |
Why?
|
| Colonic Pouches | 1 | 2006 | 99 | 0.220 |
Why?
|
| Microbial Sensitivity Tests | 4 | 2013 | 150 | 0.220 |
Why?
|
| Tetrahydrofolate Dehydrogenase | 3 | 2012 | 34 | 0.220 |
Why?
|
| Anastomosis, Surgical | 1 | 2006 | 289 | 0.220 |
Why?
|
| Epitopes | 2 | 2020 | 258 | 0.220 |
Why?
|
| Male | 23 | 2023 | 47109 | 0.210 |
Why?
|
| Cohort Studies | 6 | 2015 | 3213 | 0.210 |
Why?
|
| False Positive Reactions | 1 | 2024 | 215 | 0.200 |
Why?
|
| Monocytes | 3 | 2016 | 219 | 0.200 |
Why?
|
| Incidence | 5 | 2016 | 1777 | 0.200 |
Why?
|
| Drug Resistance | 2 | 2016 | 233 | 0.200 |
Why?
|
| Chromatography, Affinity | 1 | 2023 | 73 | 0.200 |
Why?
|
| Alleles | 3 | 2018 | 1159 | 0.200 |
Why?
|
| United States | 9 | 2018 | 8193 | 0.190 |
Why?
|
| Mitochondria | 2 | 2005 | 650 | 0.190 |
Why?
|
| CD4-Positive T-Lymphocytes | 2 | 2020 | 502 | 0.180 |
Why?
|
| Glycine | 1 | 2002 | 96 | 0.170 |
Why?
|
| Pupil Disorders | 1 | 2021 | 3 | 0.170 |
Why?
|
| Seroepidemiologic Studies | 2 | 2021 | 58 | 0.170 |
Why?
|
| Megalencephaly | 1 | 2021 | 21 | 0.170 |
Why?
|
| Pouchitis | 1 | 2001 | 58 | 0.160 |
Why?
|
| In Vitro Techniques | 2 | 2013 | 945 | 0.160 |
Why?
|
| Morbidity | 2 | 2016 | 162 | 0.160 |
Why?
|
| Neoplasms, Radiation-Induced | 1 | 2000 | 96 | 0.160 |
Why?
|
| Nitric Oxide | 2 | 2010 | 286 | 0.160 |
Why?
|
| Sequence Alignment | 4 | 2007 | 353 | 0.150 |
Why?
|
| Neurons | 1 | 2008 | 1620 | 0.150 |
Why?
|
| Virulence | 3 | 2015 | 280 | 0.150 |
Why?
|
| Adult | 17 | 2024 | 29564 | 0.150 |
Why?
|
| Soft Tissue Neoplasms | 1 | 2000 | 125 | 0.150 |
Why?
|
| Nitric Oxide Synthase | 1 | 2000 | 124 | 0.150 |
Why?
|
| HLA-DQ Antigens | 1 | 1999 | 52 | 0.150 |
Why?
|
| One Health | 1 | 2019 | 2 | 0.150 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2024 | 601 | 0.150 |
Why?
|
| Gene Frequency | 2 | 2018 | 715 | 0.150 |
Why?
|
| Disease Susceptibility | 2 | 2018 | 226 | 0.150 |
Why?
|
| Immunoassay | 2 | 2017 | 102 | 0.150 |
Why?
|
| Cell Line | 7 | 2016 | 2482 | 0.150 |
Why?
|
| Collagen Type II | 2 | 2009 | 16 | 0.140 |
Why?
|
| Vaccination | 2 | 2011 | 323 | 0.140 |
Why?
|
| Vaccines | 1 | 2000 | 86 | 0.140 |
Why?
|
| Sarcoma | 1 | 2000 | 222 | 0.140 |
Why?
|
| Inhibitory Concentration 50 | 3 | 2013 | 61 | 0.140 |
Why?
|
| Crystallography, X-Ray | 4 | 2018 | 530 | 0.140 |
Why?
|
| Radiotherapy | 1 | 2000 | 325 | 0.140 |
Why?
|
| Enzymes | 1 | 2018 | 47 | 0.140 |
Why?
|
| Spleen | 2 | 2014 | 375 | 0.140 |
Why?
|
| Risk Factors | 6 | 2021 | 6232 | 0.140 |
Why?
|
| ATP-Binding Cassette Transporters | 2 | 2009 | 144 | 0.130 |
Why?
|
| Gene Knockdown Techniques | 3 | 2018 | 256 | 0.130 |
Why?
|
| Drug Delivery Systems | 2 | 2013 | 200 | 0.130 |
Why?
|
| Bone Neoplasms | 1 | 2000 | 316 | 0.130 |
Why?
|
| T-Lymphocytes, Cytotoxic | 3 | 2010 | 321 | 0.130 |
Why?
|
| Recurrence | 5 | 2011 | 1254 | 0.130 |
Why?
|
| Panama | 1 | 2017 | 7 | 0.130 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 2013 | 1950 | 0.130 |
Why?
|
| Lymphadenitis | 1 | 1996 | 7 | 0.120 |
Why?
|
| Age Factors | 3 | 2008 | 1967 | 0.120 |
Why?
|
| Chickens | 1 | 2017 | 195 | 0.120 |
Why?
|
| Fertilization | 1 | 1996 | 42 | 0.120 |
Why?
|
| Mice, Inbred C3H | 3 | 2002 | 370 | 0.120 |
Why?
|
| Chicago | 2 | 2015 | 1513 | 0.120 |
Why?
|
| HLA-A2 Antigen | 2 | 2020 | 32 | 0.120 |
Why?
|
| Parasite Egg Count | 1 | 2016 | 7 | 0.120 |
Why?
|
| Cytochromes b | 1 | 2016 | 13 | 0.120 |
Why?
|
| Case-Control Studies | 2 | 2018 | 1996 | 0.120 |
Why?
|
| Principal Component Analysis | 1 | 2017 | 170 | 0.120 |
Why?
|
| Chronic Disease | 3 | 2008 | 985 | 0.120 |
Why?
|
| Cross-Priming | 1 | 2016 | 59 | 0.120 |
Why?
|
| Drug Administration Schedule | 2 | 2009 | 839 | 0.120 |
Why?
|
| Dogs | 1 | 2017 | 639 | 0.120 |
Why?
|
| International Classification of Diseases | 1 | 2016 | 74 | 0.120 |
Why?
|
| Animal Welfare | 1 | 2017 | 66 | 0.120 |
Why?
|
| Young Adult | 5 | 2024 | 7511 | 0.120 |
Why?
|
| Haplotypes | 1 | 2018 | 656 | 0.120 |
Why?
|
| Serogroup | 1 | 2015 | 10 | 0.120 |
Why?
|
| Anti-Bacterial Agents | 1 | 2021 | 881 | 0.120 |
Why?
|
| Morocco | 3 | 2021 | 17 | 0.120 |
Why?
|
| Urban Population | 1 | 2017 | 246 | 0.110 |
Why?
|
| Luminescent Proteins | 2 | 2013 | 142 | 0.110 |
Why?
|
| Sequence Homology, Amino Acid | 2 | 2008 | 403 | 0.110 |
Why?
|
| Immunologic Memory | 1 | 2016 | 188 | 0.110 |
Why?
|
| Bacterial Translocation | 1 | 2015 | 26 | 0.110 |
Why?
|
| Salmonella Infections, Animal | 1 | 2015 | 11 | 0.110 |
Why?
|
| Gene Regulatory Networks | 1 | 2018 | 337 | 0.110 |
Why?
|
| Chemotaxis, Leukocyte | 1 | 2015 | 39 | 0.110 |
Why?
|
| Salmonella typhimurium | 1 | 2015 | 33 | 0.110 |
Why?
|
| Intestinal Mucosa | 2 | 2015 | 834 | 0.110 |
Why?
|
| Histocompatibility Antigens Class I | 1 | 2016 | 212 | 0.110 |
Why?
|
| Crohn Disease | 2 | 2001 | 844 | 0.110 |
Why?
|
| Parasitic Sensitivity Tests | 3 | 2013 | 5 | 0.110 |
Why?
|
| Drug Therapy, Combination | 5 | 2008 | 764 | 0.100 |
Why?
|
| Feces | 1 | 2016 | 387 | 0.100 |
Why?
|
| Genes, Protozoan | 2 | 2004 | 9 | 0.100 |
Why?
|
| Receptors, Antigen, T-Cell, gamma-delta | 1 | 2015 | 119 | 0.100 |
Why?
|
| Arachidonate 12-Lipoxygenase | 1 | 2014 | 28 | 0.100 |
Why?
|
| Endoscopy | 1 | 1997 | 384 | 0.100 |
Why?
|
| Mitochondrial Proteins | 2 | 2005 | 131 | 0.100 |
Why?
|
| Surveys and Questionnaires | 2 | 2024 | 3022 | 0.100 |
Why?
|
| Visual Acuity | 4 | 2008 | 198 | 0.100 |
Why?
|
| Adenosine Triphosphatases | 1 | 2013 | 141 | 0.100 |
Why?
|
| Benzimidazoles | 1 | 2013 | 118 | 0.100 |
Why?
|
| Interleukin-1 Receptor-Associated Kinases | 1 | 2012 | 9 | 0.090 |
Why?
|
| Lymphocytes | 1 | 2015 | 461 | 0.090 |
Why?
|
| Blotting, Western | 2 | 2011 | 780 | 0.090 |
Why?
|
| Comorbidity | 1 | 2016 | 1031 | 0.090 |
Why?
|
| Binding Sites | 2 | 2013 | 1159 | 0.090 |
Why?
|
| Zebrafish | 1 | 2015 | 353 | 0.090 |
Why?
|
| Serotyping | 1 | 2012 | 28 | 0.090 |
Why?
|
| Trypanocidal Agents | 1 | 2012 | 2 | 0.090 |
Why?
|
| Leishmania donovani | 1 | 2012 | 2 | 0.090 |
Why?
|
| Trypanosoma | 1 | 2012 | 3 | 0.090 |
Why?
|
| Luciferases | 1 | 2012 | 128 | 0.090 |
Why?
|
| Imides | 1 | 2012 | 27 | 0.090 |
Why?
|
| Quantitative Structure-Activity Relationship | 1 | 2012 | 9 | 0.090 |
Why?
|
| HLA-A1 Antigen | 1 | 2011 | 1 | 0.090 |
Why?
|
| Polymerase Chain Reaction | 4 | 2017 | 895 | 0.090 |
Why?
|
| Immunity, Innate | 4 | 2015 | 481 | 0.090 |
Why?
|
| Gene Transfer Techniques | 1 | 2012 | 155 | 0.090 |
Why?
|
| Secretory Pathway | 1 | 2012 | 23 | 0.090 |
Why?
|
| Lymphocyte Activation | 3 | 2020 | 822 | 0.090 |
Why?
|
| Food Contamination | 1 | 2011 | 37 | 0.090 |
Why?
|
| Organelles | 1 | 2012 | 55 | 0.090 |
Why?
|
| Gene Expression Regulation | 4 | 2010 | 2023 | 0.090 |
Why?
|
| Bacterial Proteins | 3 | 2013 | 901 | 0.090 |
Why?
|
| Severity of Illness Index | 2 | 2009 | 2013 | 0.090 |
Why?
|
| Myosin Subfragments | 1 | 2011 | 6 | 0.080 |
Why?
|
| Models, Economic | 1 | 2011 | 62 | 0.080 |
Why?
|
| Enzyme Activation | 2 | 2013 | 679 | 0.080 |
Why?
|
| Myosin Light Chains | 1 | 2011 | 25 | 0.080 |
Why?
|
| Protein Binding | 2 | 2016 | 1554 | 0.080 |
Why?
|
| RNA, Messenger | 2 | 2012 | 2063 | 0.080 |
Why?
|
| Tetracyclines | 1 | 2010 | 5 | 0.080 |
Why?
|
| Aged | 5 | 2023 | 21760 | 0.080 |
Why?
|
| Ileum | 1 | 2011 | 172 | 0.080 |
Why?
|
| Cataract | 2 | 2011 | 87 | 0.080 |
Why?
|
| Epithelial Cells | 1 | 2015 | 709 | 0.080 |
Why?
|
| Cytochrome P-450 Enzyme Inhibitors | 1 | 2010 | 9 | 0.080 |
Why?
|
| Nitrobenzenes | 1 | 2010 | 12 | 0.080 |
Why?
|
| Eating | 1 | 2011 | 164 | 0.080 |
Why?
|
| Retinal Diseases | 2 | 2011 | 80 | 0.080 |
Why?
|
| T-Lymphocytes, Helper-Inducer | 1 | 2011 | 150 | 0.080 |
Why?
|
| Microsomes, Liver | 1 | 2010 | 48 | 0.080 |
Why?
|
| Antigens, Differentiation, T-Lymphocyte | 1 | 1990 | 98 | 0.080 |
Why?
|
| Middle Aged | 6 | 2023 | 29442 | 0.080 |
Why?
|
| Small Molecule Libraries | 1 | 2011 | 73 | 0.080 |
Why?
|
| Receptors, Purinergic P2 | 1 | 2010 | 16 | 0.080 |
Why?
|
| Immunization | 1 | 2010 | 154 | 0.080 |
Why?
|
| Protein Transport | 1 | 2012 | 448 | 0.080 |
Why?
|
| Vision Disorders | 2 | 2011 | 74 | 0.080 |
Why?
|
| Aminopeptidases | 1 | 2010 | 13 | 0.080 |
Why?
|
| HLA-B Antigens | 1 | 2010 | 32 | 0.080 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2010 | 310 | 0.080 |
Why?
|
| Minor Histocompatibility Antigens | 1 | 2010 | 41 | 0.080 |
Why?
|
| Lipopeptides | 1 | 2010 | 20 | 0.080 |
Why?
|
| Protein Biosynthesis | 1 | 2012 | 393 | 0.080 |
Why?
|
| Apoptosis Regulatory Proteins | 1 | 2010 | 201 | 0.080 |
Why?
|
| Heat-Shock Proteins | 1 | 2010 | 178 | 0.080 |
Why?
|
| RNA, Catalytic | 1 | 2010 | 137 | 0.080 |
Why?
|
| Phylogeny | 2 | 2006 | 1339 | 0.070 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2010 | 213 | 0.070 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2010 | 312 | 0.070 |
Why?
|
| Lateral Ventricles | 1 | 2008 | 12 | 0.070 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2010 | 889 | 0.070 |
Why?
|
| Retinal Hemorrhage | 1 | 2008 | 10 | 0.070 |
Why?
|
| Treatment Outcome | 5 | 2008 | 9713 | 0.070 |
Why?
|
| Choroidal Neovascularization | 1 | 2008 | 21 | 0.070 |
Why?
|
| Atrophy | 1 | 2008 | 130 | 0.070 |
Why?
|
| Galactolipids | 1 | 2008 | 2 | 0.070 |
Why?
|
| Cricetulus | 1 | 2008 | 123 | 0.070 |
Why?
|
| Intracellular Space | 1 | 2008 | 38 | 0.070 |
Why?
|
| Neonatal Screening | 1 | 2009 | 71 | 0.070 |
Why?
|
| CHO Cells | 1 | 2008 | 188 | 0.070 |
Why?
|
| NAD | 4 | 2013 | 102 | 0.070 |
Why?
|
| Microglia | 1 | 2008 | 131 | 0.070 |
Why?
|
| Protein Conformation | 3 | 2018 | 923 | 0.070 |
Why?
|
| Recombinant Proteins | 2 | 2013 | 993 | 0.070 |
Why?
|
| Cricetinae | 1 | 2008 | 533 | 0.060 |
Why?
|
| Models, Genetic | 2 | 2010 | 1005 | 0.060 |
Why?
|
| Protein Structure, Secondary | 1 | 2008 | 340 | 0.060 |
Why?
|
| Plant Proteins | 2 | 2007 | 131 | 0.060 |
Why?
|
| Epigenesis, Genetic | 2 | 2009 | 588 | 0.060 |
Why?
|
| Prenatal Care | 2 | 2024 | 81 | 0.060 |
Why?
|
| Ontario | 1 | 2006 | 32 | 0.060 |
Why?
|
| Polymorphism, Genetic | 1 | 2010 | 831 | 0.060 |
Why?
|
| Macrophages | 1 | 2010 | 643 | 0.060 |
Why?
|
| Databases as Topic | 1 | 2006 | 96 | 0.060 |
Why?
|
| Evidence-Based Medicine | 1 | 2009 | 480 | 0.060 |
Why?
|
| Lipids | 1 | 2007 | 293 | 0.060 |
Why?
|
| Eye Diseases | 2 | 2011 | 59 | 0.060 |
Why?
|
| Folic Acid Antagonists | 1 | 2005 | 17 | 0.060 |
Why?
|
| Nerve Tissue Proteins | 1 | 2008 | 512 | 0.060 |
Why?
|
| Anal Canal | 1 | 2006 | 94 | 0.060 |
Why?
|
| Eosinophilia | 1 | 2006 | 87 | 0.060 |
Why?
|
| Behavior, Animal | 1 | 2008 | 399 | 0.060 |
Why?
|
| Genome, Protozoan | 1 | 2005 | 10 | 0.060 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2008 | 1255 | 0.060 |
Why?
|
| Flow Cytometry | 2 | 2010 | 720 | 0.050 |
Why?
|
| Regression Analysis | 1 | 2006 | 580 | 0.050 |
Why?
|
| Species Specificity | 2 | 2007 | 690 | 0.050 |
Why?
|
| Rats | 2 | 2008 | 4072 | 0.050 |
Why?
|
| Gene Expression Profiling | 1 | 2010 | 1566 | 0.050 |
Why?
|
| T-Lymphocytes | 1 | 2011 | 1327 | 0.050 |
Why?
|
| Cognition Disorders | 1 | 2006 | 240 | 0.050 |
Why?
|
| Salicylamides | 1 | 2004 | 2 | 0.050 |
Why?
|
| Oxyquinoline | 1 | 2004 | 3 | 0.050 |
Why?
|
| Prospective Studies | 4 | 2023 | 4825 | 0.050 |
Why?
|
| Permeability | 2 | 2015 | 145 | 0.050 |
Why?
|
| DNA, Protozoan | 1 | 2003 | 15 | 0.050 |
Why?
|
| Feasibility Studies | 1 | 2006 | 803 | 0.050 |
Why?
|
| Leucovorin | 3 | 2008 | 205 | 0.050 |
Why?
|
| Mice, Knockout | 3 | 2015 | 2207 | 0.050 |
Why?
|
| Reoperation | 1 | 2006 | 726 | 0.050 |
Why?
|
| Histocompatibility Antigen H-2D | 1 | 2002 | 4 | 0.050 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2008 | 3618 | 0.050 |
Why?
|
| Retrospective Studies | 3 | 2006 | 10962 | 0.050 |
Why?
|
| Transcription Factors | 1 | 2010 | 1717 | 0.050 |
Why?
|
| Length of Stay | 1 | 2006 | 878 | 0.050 |
Why?
|
| Phosphorus-Oxygen Lyases | 1 | 2002 | 1 | 0.050 |
Why?
|
| Antibodies, Monoclonal | 1 | 2008 | 1416 | 0.040 |
Why?
|
| Cytotoxicity, Immunologic | 1 | 2002 | 218 | 0.040 |
Why?
|
| Crosses, Genetic | 1 | 2002 | 165 | 0.040 |
Why?
|
| Time Factors | 3 | 2018 | 5576 | 0.040 |
Why?
|
| Biomarkers | 1 | 2008 | 2022 | 0.040 |
Why?
|
| Genetic Variation | 2 | 2014 | 1445 | 0.040 |
Why?
|
| Twins, Dizygotic | 1 | 2021 | 41 | 0.040 |
Why?
|
| RNA Interference | 2 | 2014 | 388 | 0.040 |
Why?
|
| Aneuploidy | 1 | 2001 | 60 | 0.040 |
Why?
|
| Chromosomes, Human, Pair 5 | 1 | 2001 | 113 | 0.040 |
Why?
|
| Delayed Diagnosis | 1 | 2021 | 40 | 0.040 |
Why?
|
| Cognition | 1 | 2006 | 673 | 0.040 |
Why?
|
| HLA-A11 Antigen | 1 | 2020 | 2 | 0.040 |
Why?
|
| Genome | 1 | 2004 | 417 | 0.040 |
Why?
|
| Multigene Family | 1 | 2001 | 204 | 0.040 |
Why?
|
| CD8 Antigens | 2 | 2010 | 82 | 0.040 |
Why?
|
| Incidental Findings | 1 | 2021 | 100 | 0.040 |
Why?
|
| Algorithms | 1 | 2009 | 2009 | 0.040 |
Why?
|
| Parasitemia | 1 | 2000 | 7 | 0.040 |
Why?
|
| Colonic Polyps | 1 | 2001 | 140 | 0.040 |
Why?
|
| Endoscopy, Gastrointestinal | 1 | 2001 | 163 | 0.040 |
Why?
|
| Evolution, Molecular | 1 | 2006 | 902 | 0.040 |
Why?
|
| NG-Nitroarginine Methyl Ester | 1 | 2000 | 45 | 0.040 |
Why?
|
| Acetyl-CoA Carboxylase | 1 | 1999 | 6 | 0.040 |
Why?
|
| Herbicides | 1 | 1999 | 25 | 0.040 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 1 | 2000 | 238 | 0.040 |
Why?
|
| Propionates | 1 | 1999 | 28 | 0.040 |
Why?
|
| Nitric Oxide Synthase Type II | 1 | 2000 | 92 | 0.040 |
Why?
|
| Vitreous Body | 2 | 2011 | 52 | 0.040 |
Why?
|
| Signal Transduction | 1 | 2010 | 3621 | 0.040 |
Why?
|
| Protein Engineering | 1 | 2020 | 159 | 0.040 |
Why?
|
| Homozygote | 1 | 1999 | 212 | 0.040 |
Why?
|
| Animals, Wild | 1 | 2019 | 53 | 0.040 |
Why?
|
| France | 1 | 2018 | 53 | 0.040 |
Why?
|
| Survival Analysis | 1 | 2002 | 1527 | 0.030 |
Why?
|
| Sex Factors | 1 | 2002 | 1138 | 0.030 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2001 | 461 | 0.030 |
Why?
|
| Cross-Sectional Studies | 1 | 2024 | 2037 | 0.030 |
Why?
|
| Actuarial Analysis | 1 | 1997 | 60 | 0.030 |
Why?
|
| Abortion, Spontaneous | 1 | 2018 | 74 | 0.030 |
Why?
|
| Biopsy | 1 | 2001 | 1224 | 0.030 |
Why?
|
| Point-of-Care Systems | 1 | 2018 | 155 | 0.030 |
Why?
|
| Massachusetts | 1 | 2017 | 37 | 0.030 |
Why?
|
| Ohio | 1 | 2017 | 43 | 0.030 |
Why?
|
| Maryland | 1 | 2017 | 45 | 0.030 |
Why?
|
| Farms | 1 | 2017 | 11 | 0.030 |
Why?
|
| Polymorphism, Restriction Fragment Length | 1 | 2017 | 145 | 0.030 |
Why?
|
| Public Health | 1 | 2018 | 161 | 0.030 |
Why?
|
| Biological Assay | 1 | 2017 | 82 | 0.030 |
Why?
|
| Tomography Scanners, X-Ray Computed | 1 | 1996 | 23 | 0.030 |
Why?
|
| Diagnostic Tests, Routine | 1 | 2017 | 63 | 0.030 |
Why?
|
| Immunocompetence | 1 | 1996 | 26 | 0.030 |
Why?
|
| Costs and Cost Analysis | 1 | 2017 | 155 | 0.030 |
Why?
|
| Developing Countries | 1 | 2017 | 101 | 0.030 |
Why?
|
| Genetic Markers | 1 | 2017 | 471 | 0.030 |
Why?
|
| Infant, Newborn, Diseases | 1 | 1996 | 94 | 0.030 |
Why?
|
| Radiography | 1 | 1997 | 763 | 0.030 |
Why?
|
| Diagnosis, Differential | 1 | 2000 | 1568 | 0.030 |
Why?
|
| Mothers | 1 | 1996 | 146 | 0.030 |
Why?
|
| Mutation | 2 | 2002 | 4392 | 0.030 |
Why?
|
| Integrin alpha Chains | 1 | 2015 | 21 | 0.030 |
Why?
|
| Ecosystem | 1 | 2019 | 424 | 0.030 |
Why?
|
| Occludin | 1 | 2015 | 66 | 0.030 |
Why?
|
| Transplantation Chimera | 1 | 2015 | 84 | 0.030 |
Why?
|
| X-Ray Diffraction | 2 | 2006 | 131 | 0.030 |
Why?
|
| Mice, Inbred A | 1 | 1994 | 21 | 0.030 |
Why?
|
| HLA-B27 Antigen | 1 | 1994 | 8 | 0.030 |
Why?
|
| HLA-C Antigens | 1 | 1994 | 17 | 0.030 |
Why?
|
| Caspase 1 | 1 | 2014 | 22 | 0.030 |
Why?
|
| HLA-D Antigens | 1 | 1994 | 20 | 0.030 |
Why?
|
| Crystallization | 2 | 2006 | 219 | 0.030 |
Why?
|
| Arachidonic Acid | 1 | 2014 | 63 | 0.030 |
Why?
|
| Heart | 1 | 2017 | 527 | 0.030 |
Why?
|
| Colitis, Ulcerative | 1 | 2001 | 824 | 0.030 |
Why?
|
| Protein Unfolding | 1 | 2013 | 12 | 0.030 |
Why?
|
| Bone Marrow Transplantation | 1 | 2015 | 286 | 0.030 |
Why?
|
| Linkage Disequilibrium | 2 | 2008 | 483 | 0.030 |
Why?
|
| Longitudinal Studies | 2 | 2008 | 1284 | 0.020 |
Why?
|
| Molecular Conformation | 1 | 2013 | 112 | 0.020 |
Why?
|
| Molecular Docking Simulation | 1 | 2013 | 59 | 0.020 |
Why?
|
| Plasmids | 1 | 2014 | 275 | 0.020 |
Why?
|
| Temperature | 1 | 2015 | 442 | 0.020 |
Why?
|
| Caco-2 Cells | 1 | 2013 | 128 | 0.020 |
Why?
|
| High-Throughput Screening Assays | 1 | 2013 | 65 | 0.020 |
Why?
|
| Antigens, CD | 1 | 2015 | 484 | 0.020 |
Why?
|
| Hot Temperature | 1 | 2013 | 228 | 0.020 |
Why?
|
| Lymph Nodes | 1 | 1996 | 560 | 0.020 |
Why?
|
| Host-Pathogen Interactions | 1 | 2015 | 249 | 0.020 |
Why?
|
| Oxidation-Reduction | 1 | 2013 | 419 | 0.020 |
Why?
|
| Trypanosoma brucei rhodesiense | 1 | 2012 | 1 | 0.020 |
Why?
|
| Trypanosoma cruzi | 1 | 2012 | 8 | 0.020 |
Why?
|
| RNA, Small Interfering | 1 | 2014 | 564 | 0.020 |
Why?
|
| Prognosis | 1 | 2000 | 4116 | 0.020 |
Why?
|
| Th1 Cells | 1 | 2012 | 173 | 0.020 |
Why?
|
| Uveitis, Anterior | 1 | 2011 | 4 | 0.020 |
Why?
|
| Choroiditis | 1 | 2011 | 7 | 0.020 |
Why?
|
| Electrophoresis, Gel, Two-Dimensional | 1 | 2011 | 26 | 0.020 |
Why?
|
| Clinical Laboratory Techniques | 1 | 2011 | 79 | 0.020 |
Why?
|
| Immunoglobulin A | 1 | 2011 | 94 | 0.020 |
Why?
|
| Swine Diseases | 1 | 2011 | 15 | 0.020 |
Why?
|
| Optic Nerve Diseases | 1 | 2011 | 16 | 0.020 |
Why?
|
| Kinetics | 1 | 2013 | 1476 | 0.020 |
Why?
|
| North America | 1 | 2011 | 210 | 0.020 |
Why?
|
| Meat | 1 | 2011 | 27 | 0.020 |
Why?
|
| Chi-Square Distribution | 1 | 2011 | 360 | 0.020 |
Why?
|
| NLR Proteins | 1 | 2010 | 4 | 0.020 |
Why?
|
| Brazil | 1 | 2011 | 93 | 0.020 |
Why?
|
| Receptors, Purinergic P2X7 | 1 | 2010 | 10 | 0.020 |
Why?
|
| Cicatrix | 1 | 2011 | 79 | 0.020 |
Why?
|
| Cell Separation | 1 | 2010 | 200 | 0.020 |
Why?
|
| Cell Death | 1 | 2010 | 257 | 0.020 |
Why?
|
| Swine | 1 | 2011 | 593 | 0.020 |
Why?
|
| Aged, 80 and over | 1 | 2000 | 7387 | 0.020 |
Why?
|
| Oligopeptides | 1 | 2010 | 207 | 0.020 |
Why?
|
| Ranibizumab | 1 | 2008 | 14 | 0.020 |
Why?
|
| Genomic Imprinting | 1 | 2008 | 32 | 0.020 |
Why?
|
| Fluorescein Angiography | 1 | 2008 | 81 | 0.020 |
Why?
|
| Injections | 1 | 2008 | 130 | 0.020 |
Why?
|
| Microscopy, Immunoelectron | 1 | 2008 | 28 | 0.020 |
Why?
|
| Spinacia oleracea | 1 | 2008 | 16 | 0.020 |
Why?
|
| Spectrometry, Mass, Electrospray Ionization | 1 | 2007 | 23 | 0.020 |
Why?
|
| Chloroplasts | 1 | 2008 | 61 | 0.020 |
Why?
|
| B-Lymphocytes | 1 | 2012 | 727 | 0.020 |
Why?
|
| Tomography, Optical Coherence | 1 | 2008 | 129 | 0.020 |
Why?
|
| Cataract Extraction | 1 | 2007 | 31 | 0.020 |
Why?
|
| Eye | 1 | 2008 | 113 | 0.020 |
Why?
|
| Apoenzymes | 1 | 2007 | 8 | 0.020 |
Why?
|
| Mass Spectrometry | 1 | 2008 | 191 | 0.020 |
Why?
|
| Rabbits | 1 | 2008 | 581 | 0.020 |
Why?
|
| Amino Acids, Aromatic | 1 | 2006 | 3 | 0.020 |
Why?
|
| Alcohol Oxidoreductases | 1 | 2006 | 18 | 0.020 |
Why?
|
| Transferases | 1 | 2006 | 19 | 0.020 |
Why?
|
| Lyases | 1 | 2006 | 11 | 0.020 |
Why?
|
| Hydro-Lyases | 1 | 2006 | 9 | 0.020 |
Why?
|
| Wechsler Scales | 1 | 2006 | 17 | 0.020 |
Why?
|
| Prokaryotic Cells | 1 | 2006 | 14 | 0.020 |
Why?
|
| Multienzyme Complexes | 1 | 2006 | 54 | 0.020 |
Why?
|
| Vision, Monocular | 1 | 2006 | 15 | 0.020 |
Why?
|
| Intelligence Tests | 1 | 2006 | 38 | 0.020 |
Why?
|
| Macula Lutea | 1 | 2006 | 17 | 0.020 |
Why?
|
| Language Tests | 1 | 2006 | 37 | 0.020 |
Why?
|
| Computer Simulation | 1 | 2011 | 1153 | 0.020 |
Why?
|
| Gene Fusion | 1 | 2006 | 41 | 0.020 |
Why?
|
| Eukaryotic Cells | 1 | 2006 | 44 | 0.020 |
Why?
|
| Phosphotransferases (Alcohol Group Acceptor) | 1 | 2006 | 64 | 0.020 |
Why?
|
| Vision, Binocular | 1 | 2006 | 23 | 0.020 |
Why?
|
| Gene Transfer, Horizontal | 1 | 2006 | 42 | 0.010 |
Why?
|
| Eukaryota | 1 | 2006 | 48 | 0.010 |
Why?
|
| Solvents | 1 | 2006 | 91 | 0.010 |
Why?
|
| Fungi | 1 | 2006 | 70 | 0.010 |
Why?
|
| Antibodies | 1 | 2008 | 349 | 0.010 |
Why?
|
| Plants | 1 | 2006 | 122 | 0.010 |
Why?
|
| Symbiosis | 1 | 2006 | 130 | 0.010 |
Why?
|
| Water | 1 | 2007 | 310 | 0.010 |
Why?
|
| Pattern Recognition, Visual | 1 | 2006 | 163 | 0.010 |
Why?
|
| Cell Membrane | 1 | 2008 | 673 | 0.010 |
Why?
|
| Actins | 1 | 2008 | 480 | 0.010 |
Why?
|
| Inflammation | 1 | 2011 | 1120 | 0.010 |
Why?
|
| Apoptosis | 1 | 2010 | 1752 | 0.010 |
Why?
|
| Maltose-Binding Proteins | 1 | 2003 | 31 | 0.010 |
Why?
|
| Cloning, Molecular | 1 | 2003 | 581 | 0.010 |
Why?
|
| Genes, Switch | 1 | 2002 | 7 | 0.010 |
Why?
|
| Restriction Mapping | 1 | 2002 | 119 | 0.010 |
Why?
|
| Host-Parasite Interactions | 1 | 2002 | 35 | 0.010 |
Why?
|
| Antigens, Surface | 1 | 2002 | 100 | 0.010 |
Why?
|
| Gestational Age | 1 | 2003 | 341 | 0.010 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2008 | 1099 | 0.010 |
Why?
|
| Bacteria | 1 | 2006 | 545 | 0.010 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2003 | 557 | 0.010 |
Why?
|
| DNA Primers | 1 | 1999 | 530 | 0.010 |
Why?
|
| Chromosome Mapping | 1 | 2001 | 1061 | 0.010 |
Why?
|
| Transcription, Genetic | 1 | 2002 | 1133 | 0.010 |
Why?
|
| Base Sequence | 1 | 1999 | 2222 | 0.010 |
Why?
|